Drugs / GamLPV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03137927 | Jun → Dec 2017 | pertussis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04036526 | Jun 2019 → May 2020 | pertussis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GamLPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04036526 ↗ |
| Modality | Vaccine | “live intranasal vaccine for whooping cough prevention” NCT03137927 ↗ |
| Route | Intranasal | “vaccinated intranasally” NCT03137927 ↗ |